The Global Stroke Alliance Meeting held in Rio de Janeiro

The Global Stroke Alliance Meeting held in Rio de Janeiro

Source: World Stroke Organization

The Global Stroke Alliance Meeting, held in Rio de Janeiro, Brazil from March 11 to 14 was an innovative meeting that aimed to stimulate a global alliance to improve stroke care worldwide and to discuss the best strategies to implement evidence-based interventions access the continuum of care

The Global Stroke Alliance Meeting brought together leaders from 20 countries around the world with extensive experience in the organization of stroke systems of care, alongside researchers, health professionals, health managers, scientific societies, private hospitals, industry and patients associations. There were 570 in person participants and several by teleconference, with live transmission from the main sessions. The meeting reached its goal of disseminating knowledge, exchanging experiences and creating action plans tailored to each region. All actors working together, joining initiatives and adding efforts in the same direction.

In addition to representatives of international stroke societies, several representatives of Ministry of Health of Brazil and Ministry of Latin American countries, Health Secretaries from States and Cities of Brazil, the meeting included a strong participation of Dr. Anselm Hennis, Director of Non-Communicable Diseases of Pan American Health Organization from Washington – that represents World Health Organization in Americas.

The dynamics of the event included a series of forums on the most diverse themes, in an attempt to cover all fronts related to the disease -research, political, logistical and educational.

You can read the full article here.

Image by Pete Linforth from Pixabay

Can brain stimulation help your arm after stroke?

Can brain stimulation help your arm after stroke?

First published on ARNI Institute for Stroke Rehabilitation website | March 9, 2020

Neuromodulatory non-invasive brain stimulation (NIBS) techniques are experimental therapies for improving motor function after stroke. The aim of neuromodulation is to enhance adaptive or suppress maladaptive processes of post-stroke reorganisation. However, results on the effectiveness of these methods, which include transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are mixed. It’s posited that recent developments in NIBS technology will likely contribute to individualised therapy. Moving beyond single-area stimulation, targeting specific muscle groups that play different roles in post-stroke motor recovery (for example, finger flexors vs. extensors) may well be possible using multi-locus TMS. NIBS in stroke faces a challenge reminiscent of the development of other stroke therapies, such as thrombolysis and mechanical thrombectomy, where early studies were largely mixed before patient selection and individualising protocols were refined to determine its therapeutic potential.

So, researchers at UCL want to find out:

  • How brain activity changes after someone has a stroke.
  • If weak, non-invasive brain stimulation could encourage the brain into a pattern of brain activity which is useful for upper limb rehabilitation.

Please follow this link to red the full article.

Image by Gerd Altmann from Pixabay

Save the date!     World’s largest stroke congress in Vienna from May 12 to 15

Save the date!   World’s largest stroke congress in Vienna from May 12 to 15

European Stroke Organisation and World Stroke Organization Conference ESO-WSO 2020

May 12-15, 2020

Austria Center Vienna

Bruno-Kreisky-Platz 1

1220 Vienna, Austria

The world’s largest and most important congress on the subject of stroke will take place in Austria’s capital from May 12 to 15. For the first time, the European Stroke Organisation (ESO) and the World Stroke Organization (WSO) are jointly organizing this expert conference. Around 6,500 participants are expected, including leading stroke specialists from all over the world. More than 3,000 abstracts have been submitted.

In addition to the initial presentation of large clinical studies, important current topics such as the increasing significance of thrombectomy will be discussed. Another major focus is stroke prevention, which is a global challenge.

For further details on the ESO-WSO 2020, please visit

If you have not yet put a placeholder in your diary for this important event, we encourage you to do so.

Media registration is open – please send an e-mail to

Press contact
Urban & Schenk medical media consulting
Barbara Urban: +43 664/41 69 4 59,
Harald Schenk: +43 664/160 75 99,

Yours sincerely,

Prof. Jesse Dawson (ESO)                                    Prof. Michael Brainin (WSO)
Co-Chair of the Conference Planning Group       Co-Chair of the Conference Planning Group

Dr. Mira Katan, Prof. Patrik Michel, Prof. Stefan Kiechl, Dr. Vasantha Padma,
Dr. Diana Aquiar de Sousa, Dr. Yvonne Chun (PR Committee / Press Liaison)

Barbara Urban, Harald Schenk (PR Liaison)

Round Table: Peer to peer discussion on the role of anticoagulation in the setting of cerebral venous thromboembolism

Round Table: Peer to peer discussion on the role of anticoagulation in the setting of cerebral venous thromboembolism

Please find below a link to access the new Oruen Round Table. Please be advised that this is for medical professionals.

This is a peer to peer discussion on the role of anticoagulation in the setting of cerebral venous thromboembolism.

  • CVT is a rare type of stroke and peripheral venous thromboembolism
  • There is scientific evidence supporting anticoagulation in the acute phase of CVT but scant data to guide longer-term oral anticoagulation
  • Non-vitamin-K oral anticoagulants (NOACs) are being investigated as an alternative to warfarin in patients with CVT for longer-term management

This discussion’s audience is for the general neurologists and stroke specialists across Europe, once completed, learners will be able to:

  • Discuss risk of venous thromboembolism (VTE) after cerebral venous thrombosis (CVT)
  • Explain the design of RE-SPECT CVT trial
  • Analyse outcomes in RE-SPECT CVT trial

(please note this content is not available for physicians in the UK & US)


José Ferro
Department of Neurosciences and Mental Health
Hospital Santa Maria/Centro Hospitalar Universitário Lisboa Norte
Lisbon, Portugal

Hans-Christoph Diener
Faculty of Medicine
University Duisburg-Essen
Essen, Germany

Jonathan Coutinho
Department of Neurology
Academic Medical Center University of Amsterdam
Amsterdam, The Netherlands

This round table discussion was filmed in Amsterdam by Oruen and was supported by Boehringer Ingelheim.  

This discussion has been awarded 1 CME credit by the EACIC; instructions on how to obtain your CME credit will follow at the end of this video.


New Stroke Outcome Data: If we have longer monitoring after stroke, would we have even better outcomes?

New Stroke Outcome Data: If we have longer monitoring after stroke, would we have even better outcomes?

Professor Valeria Caso, Associate Professor of Neurology, University of Perugia Stroke Unit, Perugia, Italy, Professor Helmut Pürerfellner, Department of Cardiology, Public Hospital Elisabethinen, Linz, Austria and Professor Georgios Tsivgoulis, Associate Professor of Neurology, Second Department of Neurology, National & Kapodistrian University of Athens, Greece discussed the different types of stroke and how it is a major healthcare issue. They also discussed the value of prolonged monitoring in selected ESUS patients, and also some new data that might reconfirm what we already know – that if we have longer monitoring in some of those patients, then we will have even better outcomes.

Learning Objectives

  • New evidence and increasing the awareness of atrial fibrillation (AF) in cryptogenic stroke patients.
  • Treatment approaches from the guidelines and the latest study evidence.
  • AF, stroke, and related symptoms, and why the evidence from the past is important.
  • Why ESUS needs prolonged monitoring and how new data may benefit patients.

For accessing the webinar video, please click on the button below:

Oruen Webinar

For further information please visit Oruen website.

This webinar was supported by Medtronic.





Women’s blood vessels age faster than men’s

Women’s blood vessels age faster than men’s

First published on

New research from the Smidt Heart Institute at Cedars-Sinai showed for the first time that women’s blood vessels — including both large and small arteries — age at a faster rate than men’s. The findings, published Wednesday in the journal JAMA Cardiology, could help to explain why women tend to develop different types of cardiovascular disease and with different timing than men.

“Many of us in medicine have long believed that women simply ‘catch up’ to men in terms of their cardiovascular risk,” said Susan Cheng, MD, MPH, MMSc, senior author of the study and director of Public Health Research at the Smidt Heart Institute. “Our research not only confirms that women have different biology and physiology than their male counterparts, but also illustrates why it is that women may be more susceptible to developing certain types of cardiovascular disease and at different points in life.”

Using community-based data amassed from multiple sites across the country, Cheng and her research team conducted sex-specific analyses of measured blood pressure — a critical indicator of cardiovascular risk. The data represented nearly 145,000 blood pressure measurements, collected serially over a 43-year period, from 32,833 study participants ranging in age from 5 to 98 years old.

Because a person’s risk for developing a heart attack, heart failure, or a stroke typically begins with having high blood pressure, Cedars-Sinai researchers combed through their massive data looking for clues and patterns regarding how blood pressure starts to rise. Then, instead of comparing the data from men and women to each other, investigators compared women to women and men to men.

This approach allowed investigators to identify that the progression and evolution of women’s vascular function is very different than for men. In fact, women showed signs of blood pressure elevation much earlier in life than men.

“Our data showed that rates of accelerating blood pressure elevation were significantly higher in women than men, starting earlier in life,” said Cheng, the Erika J. Glazer Chair in Women’s Cardiovascular Health, who also serves as director of Cardiovascular Population Sciences at the Barbra Streisand Women’s Heart Center. “This means that if we define the hypertension threshold the exact same way, a 30-year old woman with high blood pressure is probably at higher risk for cardiovascular disease than a man with high blood pressure at the same age.”

Christine Albert, MD, MPH, founding chair of the newly established Department of Cardiology at the Smidt Heart Institute, says this new research should help guide clinicians and researchers to think differently when it comes to treating and studying women and their cardiovascular health.

You can read the full article here.
Image: Pixabay